Life Sciences

Corcept’s ALS Modulator Fails to Meet Primary Endpoint ...

After Amylyx and PTC, Corcept has also decided to withdraw from the amyotrophic ...

FDA Identifies Further Safety Concerns With Intercept’s...

The Food and Drug Administration (FDA) has uncovered additional safety concerns ...

Ro Partners With Eli Lilly to Offer Zepbound, a Weight-...

Ro, a direct-to-consumer health and wellness company, has announced a partnershi...

Carisma to undergo staff and clinical candidate restruc...

Carisma, a Philadelphia-based biotech company, is undergoing significant restruc...

BioAge Halts Phase 2 Obesity Study Just Two Months Afte...

BioAge Labs, a recent success in the biotechnology IPO market, has made a surpri...

Novocure’s Wearable Therapy Shows Promise in Treating P...

As part of a first-line treatment for patients with inoperable pancreatic adenoc...

Novartis Shells Out $1B Upfront to PTC For Midphase Hun...

Novartis has paid out $1 billion upfront for worldwide rights to PTC Therapeutic...

GE HealthCare to Acquire Japanese Radiopharmaceutical B...

Likely to be effective next year, GE HealthCare will assume full control of Niho...

The now-urgent automation agenda: out-of-control regula...

A new independent survey of senior US pharma regulatory professionals suggests t...

Research finds Merck’s treatment of lung disease can lo...

Merck has released that its drug, Winrevair, reduced the risk of death in patien...

Biohaven’s SMA drug fails to produce statistically sign...

A late-stage study testing the efficacy of Biohaven’s taldefgrobep alpha against...

Jazz’s HER2 Bispecific Gets FDA Green Light

A bispecific antibody has emerged in the HER2 arena, exhibiting a different prof...

J&J and Protagonist Therapeutics’ Oral Psoriasis Drug S...

Hailed as the first oral peptide designed to selectively block IL-23, Johnson & ...

Incyte’s $750M Acquisition Shaken by Key Trial Pause an...

Incyte faced severe difficulties just a few months after purchasing Escient Phar...

71% of Patients in Cybin’s Small Depression Study Are i...

The Canada-based biotechnology company Cybin has announced the results of a Phas...

Roche Partners with Transcription Factor Pioneer Flare ...

Roche has entered a groundbreaking deal worth more than $1.8B with Flare Therape...